![]()
|
|
||||||||
J Biol Chem, Vol. 274, Issue 51, 36219-36225, December 17, 1999
,
From the Mike Rosenbloom Laboratory for Cardiovascular Research, McGill University Health Centre, Montreal, Quebec, Canada, H3A 1A1 Canada and § Department of Nutrition, University of California, Davis, California 95616
| |
ABSTRACT |
|---|
|
|
|---|
Acylation stimulating protein (ASP) is a potent
stimulator of triglyceride synthesis in adipocytes. In the present
study, we have examined the effect of an ASP functional knockout
(ASP( Acylation stimulating protein
(ASP)1 is a 76-amino acid
protein identical to C3adesArg, a cleavage product of complement C3. Extensive in vitro data demonstrate an ASP effect on fatty
acid esterification in human and murine adipocytes and preadipocytes (1-3) as well as human fibroblasts (4-6). Recently, it has been demonstrated that ASP also inhibits hormone-sensitive lipase through an
effect on phosphodiesterase 3 (PDE3) (7). ASP also stimulates glucose
transport in human and murine adipocytes and preadipocytes (2, 8) as
well as human fibroblasts (4) and differentiated rat muscle cells (9).
This effect on glucose transport is consequent to translocation of Glut
1 or Glut 3 or Glut 4 (depending on the particular cell). The effects
of ASP are likely mediated through interaction with a specific cell
surface receptor that demonstrates high affinity binding and
tissue-specific distribution (for a review on ASP see Ref. 3). Adipose
tissue mass is determined by the rate of the opposing reactions,
triglyceride synthesis, and lipolysis. Since ASP stimulates
triglyceride synthesis and inhibits lipolysis and does so independently
and additively with insulin (4, 7-9), ASP has the potential to
profoundly influence adipose tissue metabolism.
ASP is produced through the interaction of complement C3, factor B, and
adipsin (10, 11), and all three factors are expressed and secreted by
human and murine adipocytes in a differentiation-dependent manner (1, 12, 13). The production of ASP by cultured adipocytes is
stimulated by chylomicrons (14, 15). Although there is substantial
in vitro data on ASP production, there have been far less
in vivo studies to date on ASP. In the general circulation there appears to be a slight decrease in ASP over time following a fat
load (16). However, generation of ASP
does increase postprandially locally across an arterial-venous adipose
tissue gradient (17) but not across a muscle gradient.2 Our
hypothesis is that ASP increases the efficiency of dietary energy
storage through its cellular effects on lipid and glucose tissue storage.
The development of C3 knockout mice (18) allowed us the opportunity to
examine the effects of an obligatory ASP knockout (since the precursor
to ASP, C3, is absent in mouse plasma) on postprandial metabolism. In
our first study on young (8-10 weeks old) male and female mice, we
demonstrated increased postprandial triglyceride (TG) in the ASP( The aim of the present study was to examine the ASP( Ethics--
All experimental protocols were approved by the
Royal Victoria Hospital Animal Ethics committee and were in accordance
with the guidelines set out by the Canadian Committee on Animal Care.
Mice--
Dr. H. Colten and Dr. R. H. Wetsel kindly
provided the knockout and wild type mice for breeding. Development of
the complement C3 knockout has been described elsewhere in detail (18,
21). The mice were of (129Sv × C57Bl/6) strain, and heterozygous
mating produced the littermates (wild type ASP(+/+) and knockout
ASP( Genotyping--
For genotyping, tail DNA was extracted, and
polymerase chain reaction was performed. Polymerase chain reaction was
performed using 800 nM each of the following primers: C3
sense, CTT AAC TGT CCC ACT GCC AAG AAA CCG TCC CAG ATC; C3 antisense,
CTC TGG TCC CTC CCT GTT CCT GCA CCA GGG ACT GCC CAA AAT TTC GCA AC;
neomycin sense, ATC GCA TCG AGC GAG CAC GTA CTC GGA; neomycin
antisense, AGC TCT TCA GCA ATA TCA CGG CTA GCC. Polymerase chain
reaction conditions were 30 cycles at 94 °C for 1 min, 67 °C for
2 min, and 72 °C for 3 min. Products were separated by
electrophoresis on a 7% polyacrylamide gel and visualized with
ethidium bromide staining.
Diet, Feeding, and Weighing--
ASP(+/+) and ASP( Plasma Assays--
Blood was collected by tail bleeding into
EDTA-containing tubes by tail bleeding as described previously (19, 20)
from mice fasted overnight (16 h) with water ad libitum at
10, 16, 28, and 32 weeks of age. Blood was separated by centrifugation, and the plasma was stored at Fat Load--
After an overnight fast (16 h), 400 µl of olive
oil (followed by 100 µl of air) was given by gastric gavage using a
feeding tube (1-cm curved ball tipped feeding needle 20), according to standard procedures as published previously (19, 20) and similar to
previously published methods (24-27). Blood (40 µl) was collected by
tail bleeding at 0, 1, 2, 3, 4, and 6 h.
Glucose Load--
For glucose tolerance tests, mice were fasted
overnight for 16 h with water ad libitum. Basal blood
was taken (80 µl), and mice were injected intraperitoneally with a
sterile D-glucose solution in saline, 2 mg/g of body weight
from a stock solution of 200 mg/ml (0.010 ml/g of body weight). Blood
was collected at 15, 30, 60, 90, and 120 min. Insulin and glucose were
measured 0, 30, 60, and 120 min (80 µl collected), and glucose only
was measured at 15 and 90 min (20 µl collected).
Statistical Analyses--
Results are presented as the mean ± S.E. The two groups were compared by repeated measures of two-way
ANOVA followed by Bonferroni post-test or by the area under the curve
(AUC) (for time course data), t test, ANOVA (fasting data),
or Pearson correlation using computer-assisted analysis (Sigma Stat,
Jandel Scientific, San Rafael, CA and Prism, GraphPad San Diego, CA).
Mice were examined at three time points, at 10 weeks of age, 14 weeks of age (after 1 month on a low fat or a high fat diet), and again
at 26 weeks of age (after a total of 4 months on a low fat or high fat
diet). The diets contained a fixed amount of protein (20%), and as the
fat content was increased (10% to 40% of energy), the carbohydrate
contribution was proportionally reduced (70 to 40% of energy). Basal
fasting lipids for male wild type ASP(+/+) and male knockout ASP(
/
)) on lipid metabolism in male mice. In both young (14 weeks)
and older (26 weeks) mice there were marked delays in postprandial triglyceride clearance (80% increase at 14 weeks and 120% increase at
26 weeks versus wild type (+/+)). Postprandial
nonesterified fatty acids were also increased in ASP(
/
) mice
versus ASP(+/+) mice by 37% (low fat 10% Kcal) and by
73% (high fat 40% Kcal) diets, although there were no differences in
fasting lipid levels. The ASP(
/
) mice had moderately increased
energy intake (16% ± 2% p < 0.0001) and reduced
feed efficiency (33% increase in calories/g of body weight gained on
low fat diet) versus wild type. The ASP(
/
) mice also
had modest changes in insulin/glucose metabolism (30% to 40% decrease
in insulin·glucose product), implying increased insulin sensitivity.
As well, there were decreases in leptin (29% shift in leptin to body
weight ratio) and up to a 26% decrease in specific adipose tissue
depots versus the wild type mice on both low fat and high
fat diets. These results demonstrate that ASP plays an important role
in adipose tissue metabolism and fat partitioning.
![]()
INTRODUCTION
TOP
ABSTRACT
INTRODUCTION
MATERIALS AND METHODS
RESULTS
DISCUSSION
REFERENCES
/
)
mice in the absence of any change in fasting TG (19). These effects
were more pronounced in the males than in the females. Conversely,
administration of ASP to ASP(
/
) mice (19) or to wild type Black6
mice (20) enhanced the clearance of triglyceride and decreased
postprandial lipemia.
/
) phenotype in
more detail in a longitudinal study with different diets (10% low fat
and 40% high fat). We postulated that the wild type ASP(+/+) mice on
the high fat diet would mimic the knockout ASP(
/
) phenotype and
that the high fat diet would amplify the effects of the ASP(
/
) phenotype.
![]()
MATERIALS AND METHODS
TOP
ABSTRACT
INTRODUCTION
MATERIALS AND METHODS
RESULTS
DISCUSSION
REFERENCES
/
)) used for the present experiments. Mice were housed in
sterile barrier facilities with equal day/night periods. In all cases, littermates were used to randomize genetic variation.
/
) male
mice were weighed once weekly from weaning at 4 weeks of age. At 8 weeks, the mice were housed individually and allowed to acclimatize for
2 weeks. At 10 weeks of age, the mice were placed on a pelleted low fat
diet (LF) consisting of 19.3% protein, 67.3% carbohydrate, and 4.3%
fat (w/w) or high fat diet (HF) consisting of 22.9% protein, 45.8%
carbohydrate, and 20.3% fat w/w modified from Van Heek et
al. (22) and obtained from Research Diets, Inc. (New Brunswick,
NJ) (Diets D12477 and D12478, respectively). The diets contained 10%
Kcal (LF) and 40% Kcal (HF) energy from fat, with a 1:1:1 ratio of
saturated:monounsaturated: polyunsaturated fats and were stored at
4 °C. Carbohydrate was in the form of cornstarch rather than sucrose
(70% LF and 40% HF Kcal). The vitamin and mineral content conformed
with the AIN (American Institutes of Nutrition) guidelines. The food
was weighed 3 times weekly over a period of 16 weeks, and food intake
was determined over the time period of 10 to 26 weeks of age. After 1 month on the diet, a fat load was performed, and 2 weeks later a
fasting blood samples was taken. The same treatment was repeated at 4 months on the diet (26 and 28 weeks of age). On a subset of mice, a
glucose tolerance test was performed at 30 weeks of age, and mice were
sacrificed at 32 weeks or 48 weeks. Mice were anesthetized (0.01 ml/10
g of body weight intramuscularly) with a mixture composed of 5 ml of
ketamine (100 mg/ml), 2.5 ml of xylazine (20 mg/ml), 1 ml of
acepromazine (10 mg/ml), and 1.5 ml of sterile saline. Blood was drawn
from the tail (0.5 ml), and the mice were sacrificed by cervical
dislocation. Tissues were dissected, weighed, and frozen in liquid
nitrogen. Four adipose tissues depots were collected: inguinal,
pectoral and suprascapular together, gonadal fat up to the apex of the
ovary, and perirenal adipose tissue with the adrenal gland removed.
Additional tissues collected were heart, liver, intrascapular and
scapular brown adipose tissue, both kidneys, and quadriceps muscles
with all visible fat removed.
80 °C. Leptin was measured using a
mouse leptin radioimmunoassay (Linco Inc. St Charles, MO) as described
previously (23). Fasting insulin was measured using a rat insulin
radioimmunoassay kit that had 100% cross-reactivity to mouse insulin
(as described by the manufacturer, Linco Inc). Glucose was measured
using a Trinder glucose kit (Sigma). Plasma free fatty acids (NEFA),
cholesterol, and triglycerides were measured using colorimetric
enzymatic kits (Roche Molecular Biochemicals).
![]()
RESULTS
TOP
ABSTRACT
INTRODUCTION
MATERIALS AND METHODS
RESULTS
DISCUSSION
REFERENCES
/
)
mice are shown in Table I. Overall there
was no change in plasma TG between the wild type ASP(+/+) and
ASP(
/
) mice, nor was there any effect of diet or age. Plasma cholesterol (CHOL) on the other hand increased with age and also increased on a high fat diet, as has been reported elsewhere (28-30). Although there appeared to be a trend toward increased plasma CHOL in
the (
/
) mice, especially in the older mice, the differences were
not significant and were due primarily to increases in HDL CHOL in the
ASP(
/
) knockout with no change in VLDL + LDL CHOL (results not
shown). Plasma NEFA decreased with age as seen previously (31),
although there was no effect of the high fat diet on these parameters.
Although young ASP(
/
) mice (10 weeks old) had higher plasma NEFA
and slightly increased VLDL + LDL CHOL versus wild type, as
shown previously (19), this was not apparent as the mice aged.
Fasting plasma lipids in ASP (
/
) and ASP (+/+) mice
/
) and (+/+) mice at the
indicated ages (sample size indicated for each group). Values are
expressed as the average ± S.E.
We have previously demonstrated that young male ASP(
/
) mice (8-10
weeks old) demonstrate small but significant delays in TG clearance
following a fat load with a 52% increase in TG AUC (19). As shown in
Fig. 1, at 14 weeks of age (on a low fat
diet) there is a substantial difference in postprandial TG in the
ASP(
/
) as compared with ASP(+/+) (893 ± 279 (
/
)
versus 497 ± 90 (+/+) AUC mg/dl·h, an 80% increase,
p < 0.02). There is no difference in the NEFA
postprandial profile between the two groups (Fig. 1, right
panel). The postprandial TG curves after 1 month on the HF diet
are shown in Fig. 2. The high fat diet
results in a delay in postprandial TG clearance in the ASP(+/+) mice
such that the TG AUC increases by 65% versus the ASP(+/+)
control on LF (820 ± 149 mg/dl·h, p < 0.01).
The postprandial curve of the ASP(
/
) mice slightly increased as
compared with the ASP(
/
) on LF diet (1094 ± 242 mg/dl·h
AUC). However, in the ASP(
/
) mice on HF there was also a pronounced
increase in the postprandial plasma NEFA (2.5 fold) that did not occur
in the ASP(+/+) mice on the high fat diet (Fig. 2, right
panel).
|
|
After a total of 4 months on the respective diets, we reexamined
postprandial responses in the mice. The results for TG AUC for 10 weeks
of age, 1 month on diet (14 weeks of age), and 4 months on diet (26 weeks of age) are shown in Fig. 3. In the
ASP(+/+) mice, there are progressive diet-induced increases in TG AUC. In the ASP(
/
) mice there are also marked changes in TG AUC that in
most instances are larger than the wild type. The differences in TG AUC
between ASP(+/+) and ASP(
/
) are not secondary to differences in
basal TG levels, since there is no change in fasting TG levels (Table
I). At 1 month (low and high fat diet) and 4 months (low fat diet) the
TG AUC in ASP(
/
) is significantly increased compared with ASP(+/+).
At 4 months on the high fat diet, the TG AUC for ASP(
/
) is reduced
compared with HF ASP(+/+) but is still significantly increased over the
LF ASP(+/+) control.
|
The results for NEFA at 4 months are shown in Fig.
4 for low fat (left panel) and
high fat (right panel). In the wild type mice, the increase
in postprandial NEFA AUC is modest (20.6% increase over basal AUC for
LF and 30.8% for HF diet). By contrast, the increase in NEFA in the
ASP(
/
) mice is greater than the (+/+) mice, 45% on LF and 70% on
HF (p < 0.003 and p < 0.0001, respectively, by two-way repeated measures ANOVA).
|
We also examined glucose and insulin metabolism in the mice. Fasting
glucose and insulin are given in Table
II. High fat diets are recognized for
their effects on inducing insulin resistance and disordered glucose
metabolism (28-30, 32-34). In the ASP(+/+) mice, there is a slight
increase in glucose with age, as well as an effect of the high fat diet
that increases glucose by 9% on average. There is a similar high fat
effect on insulin that increases by 2-fold at both 1 month and 4 months
on the diet. In the ASP(
/
) mice, there is a similar increase in
insulin with age and diet. However, the ASP(
/
) have significantly
lower glucose levels than the wild type at 14 and 26 weeks old at any
given insulin level, and this is evidenced by the reduced
insulin·glucose product, which is lower in the ASP(
/
) mice. This
relationship between insulin and glucose in ASP(+/+) and ASP(
/
) was
analyzed by linear regression analysis, and for any given value of
insulin, the corresponding glucose is significantly lower in the
ASP(
/
) as compared with ASP(+/+) (p < 0.002).
|
Postprandial glucose after a fat load at either 1 month or 4 months on
LF or HF was no different in ASP(+/+) versus (
/
) (Table
III). In a subset of mice we also
measured plasma glucose after a glucose tolerance test (GTT) at 4.5 months on LF or HF diet, and again there was no difference in ASP(+/+)
versus (
/
) (Table III). There was a clear effect of the
high fat diet in both wild type and knockout mice (Table III) where
glucose AUC increased 29 to 47% and was significant in all cases.
Finally, GTT insulin response increased with a high fat diet in both
ASP(+/+) and (
/
) but to a lesser extent in (
/
), and on the LF
diet only the insulin response to GTT was significantly lower in
ASP(
/
) versus ASP(+/+), p < 0.02.
|
We also looked at other factors related to energy nutrient disposition
and fat mass: growth curves of the mice, body composition, leptin and
food efficiency. The mice were weighed each week from 4 to 26 weeks
old, and the food intake monitored over the dietary period (16 weeks
from 10 to 26 weeks of age). Although the knockout mice were slightly
heavier at all ages versus (+/+) by 9% ± 0.9% (LF) and
4.1% ± 0.3% (HF), the differences were not significant. Total body
weight on high fat diets, relative to low fat diet, increased to the
same extent in both ASP(+/+) and ASP(
/
) by 22.5% ± 2.1% (+/+)
and 18.7% ± 1.7% (
/
) over the 4-month period. Leptin, which
correlates very highly to body weight and adipose tissue mass, was
measured at several time points from 10 to 32 weeks of age as an index
of adiposity in the mice. Leptin increases both with age and with diet
in wild type mice, as reported by others (22, 23, 35), and this was
also true of the ASP(
/
) mice. However, as shown in Fig.
5, relative to body weight, there was
always significantly less leptin in ASP(
/
) versus (+/+), p < 0.006, suggesting reduced whole body fat. This
decrease in leptin was reflected by small but significant decreases in
adipose tissue mass (Table IV)
particularly in the gonadal and perirenal fat (
26% and
13% (LF),
respectively), representing a decrease from 6.3% ASP(+/+) to 4.2%
ASP(
/
) fat versus body weight. On the other hand, there
was a significant increase in intrascapular brown adipose tissue in the
ASP(
/
) mice versus ASP(+/+) on both the low and high fat
diets (89 and 39%, respectively, p < 0.05).
|
|
Finally, the ASP(
/
) mice appeared to be mildly hyperphagic,
possibly as a result of decreased leptin levels. As shown in Fig.
6, (low fat diet) there was little
difference in energy intake in ASP(+/+) versus (
/
) in
the first 5 weeks after the change to a low fat or high fat diet.
However, after this adjustment period the ASP(
/
) mice consistently
consumed a greater caloric load (112 ± 1.8 ASP(
/
)
versus 95.4 ± 0.8 ASP(+/+) cal/week, a 17% increase
for ASP(
/
) versus wild type, p < 0.0001 by two way repeated measures ANOVA). This was also true on the high fat diet (similar profiles), although to a lesser extent, since all mice
tended to increase their energy intake on a high fat diet (average
131.4 ± 3.8 ASP(
/
) versus 125.7 ± 2.8 ASP(+/+) cal/week, a 6% increase for ASP(
/
) versus wild
type, p = 0.07). When energy intake is calculated
relative to an increase in body weight (feed efficiency) over the
16-week period, the ASP(
/
) mice had a lower feed efficiency
(i.e. required more energy intake relative to body weight
gained) as compared with the ASP(+/+) on both the low fat diet
(148 ± 19 ASP(
/
) versus 111 ± 16 ASP(+/+)
cal/g of body weight gained, 33% increase, p < 0.001)
and high fat diet (109 ± 18 ASP(
/
) versus
98.3 ± 8 ASP(+/+) cal/g of body weight gained, 11% increase,
p = 0.07).
|
| |
DISCUSSION |
|---|
|
|
|---|
In the present study we have examined in detail the ASP knockout phenotype in male mice. These mice are characterized by 1) marked postprandial lipemia (triglycerides) and increased postprandial nonesterified fatty acid levels on both low and high fat diets, 2) increased energy intake/feed efficiency, and 3) modest changes in insulin/glucose metabolism and leptin/adiposity. On the other hand, in the female mice (reported elsewhere), although the changes were directionally the same, the female mice demonstrated greater changes in insulin/glucose metabolism and leptin/adiposity, with smaller changes in free fatty acids and, surprisingly, no postprandial lipemia. In both types of mice, however, there were changes in energy intake/feed efficiency.
Two characteristics of the ASP(
/
) male mice were (i) the presence
of marked postprandial lipemia in the ASP(
/
) mice and (ii)
increased energy intake/reduced feed efficiency. Increased postprandial
lipemia as well as increased energy intake are also characteristic of
wild type mice that have been maintained on a high fat diet (24, 36).
However, the similarities between the ASP(
/
) phenotype and high fat
diets in wild type mice end there. Although the ASP(
/
) mice
demonstrate improved insulin/glucose, reduced leptin/adiposity, and
increased postprandial free fatty acids, wild type mice on a high fat
diet are characterized by increased glucose and insulin, insulin
resistance, increased leptin, increased adipose tissue stores, and no
dietary effect on free fatty acids. In fact, the ASP(
/
) phenotype
is maintained even when the mice are placed on a high fat diet. The
metabolic consequences (as discussed below) might be expected to be
different between the two phenotypes.
Postprandial triglycerides are cleared from the circulation in a
two-step coupled process. First, triglycerides are hydrolyzed by the
rate-limiting enzyme lipoprotein lipase (LPL), and second, the free
fatty acids generated are cleared from the circulation by uptake into
target tissues (white and brown adipose tissue, muscle, and liver).
Thus clearance of triglycerides will, in the first instance, be
regulated by the mass and activity of LPL, which can be influenced
genetically by mutation (37), overexpression (38), or knockout of LPL
(26). Environmentally, the major influences on LPL are gender and the
influence of sex hormones (39), insulin levels and insulin sensitivity
(40), and inhibition by the local level of NEFA (41-43). On a high fat
diet, wild type (+/+) mice develop postprandial lipemia, probably due
to reduced insulin sensitivity or its reduced effects on LPL. On the
other hand, in the male ASP(
/
) mice, the lack of ASP results in
increased circulating concentrations of NEFA and delays in tissue free
fatty acid uptake, and this may inhibit LPL. As compared with the
female mice, male wild type mice have reduced adipose tissue mass (44), decreased LPL (45), and increased insulin levels (46) and are more
sensitive to high fat diet-induced insulin resistance (31). These
factors may compound the effect of ASP deficiency, resulting in a
pronounced delay in postprandial TG clearance. Conversely, in the
female ASP(
/
) mice, the postprandial NEFA do not reach the same
levels as in the males, and there is no enhanced postprandial lipemia.
The most likely explanations are (i) increased adipose tissue mass
(relative to the males), which thus providing more LPL and more tissue
available for fatty acid uptake and esterification, coupled to (ii)
increased insulin sensitivity to stimulate LPL activity and fatty acid
esterification. Thus alternate mechanisms in female mice may help to
compensate for the lack of ASP.
We have previously demonstrated this same profile of postprandial
lipemia (although to a lesser extent) in younger male ASP(
/
) mice
(19). By contrast, Wetsel et al. (47) have not demonstrated a difference in postprandial triglycerides in their study. In their
study, they also did not find lower postprandial triglycerides in
female versus male mice, and their female mice demonstrated higher apoB levels than males. The lack of sexual dimorphism is unusual
considering the well recognized differences that have been reported
elsewhere (24, 31, 45, 48) and that we have also seen in both the
ASP(+/+) and the ASP(
/
) mice (19).
One explanation for the differences may lie in the colony
characteristics. Both colonies are a genetic hybrid of C57Bl/6 and 129Sv, and this genetic heterogeneity is controlled for in both studies
through the use of ASP(
/
) and (+/+) littermates for the
comparisons. However the relative contribution of each background strain in our mice colony may be different from theirs. We have back-crossed the ASP(
/
) onto each of these two different strains to
98% genetic homogeneity (6-generation back-cross). Not only are there
strain differences in the fasting lipids (as reported elsewhere (24,
49, 50) 2) and postprandial profiles in the wild type, more
notably there is also differential expression of the ASP(
/
)
phenotype, at least as far as postprandial triglycerides are
concerned.3 The different
insulin levels measured in these two mice strains may account for these
differences. This is consistent with different insulin sensitivity
between mouse strains, which may help to compensate for the lack of
ASP. In fact, strain-specific phenotypic expression of knockouts or
naturally arising mutations are not uncommon.
The association of increased postprandial NEFA, decreased glucose
relative to insulin, and decreased leptin/adiposity is interesting with
respect to the potential metabolic changes. In the first instance, a
decreased glucose-to-insulin ratio would suggest increased insulin
sensitivity in ASP(
/
) mice. This increased insulin sensitivity coupled to the reduced leptin and adipose tissue mass would provide a
strong metabolic drive toward increased energy intake and partitioning of calories to the adipose tissue, leading to obesity. Thus it is even
more striking that, despite the slightly increased calorie-to-body weight intake, even on a high fat diet, the ASP(
/
) mice are not
more obese than their (+/+) counterparts. This highlights the important
physiological function of ASP, which may be necessary for efficient
regulation of adipsoe tissue metabolism.
The increased postprandial NEFA coupled to the lower glucose-to-insulin
ratio suggests that there may also be changes in nutrient partitioning.
We would hypothesize that the decreased efficiency of NEFA uptake may
result in enhanced utilization of glucose, resulting in lowered plasma
glucose levels and greater insulin sensitivity. When delivery of NEFA
to tissues was disrupted by a targeted knockout of LPL, fasting plasma
glucose was lower and even led to neonatal death (51). Similarily, with
GLUT 4 overexpression in mice, it was suggested that the increased
glucose uptake and storage into adipose tissue caused decreased NEFA
adipose tissue uptake and repartitioning of the available NEFA to
muscle and brown adipose tissue, resulting in increased NEFA oxidation
(52). This same process may be occurring in the ASP(
/
) mice. The
increase in brown adipose tissue mass would point in that direction,
and these issues are being explored presently.
In humans, there is considerable evidence suggesting that (i) the association between obesity and glucose/insulin resistance/diabetes as well as (ii) the association between obesity and hyperlipidaemia/hyperapoB are mediated by alterations in plasma NEFA and are collectively known as "syndrome X" (53). Randle et al. (54) and more recently Bjorntorp (55) and McGarry (56) as well as others have proposed that the muscle competition for NEFA/glucose utilization as well as NEFA effects on hepatic metabolism, reduced insulin removal, and increased pancreatic insulin secretion are the cause of these complications. These same authors have also documented the link between NEFA and increased VLDL and apoB lipoprotein secretion. In this scenario, any disturbance that increases plasma NEFA would play a causative role, whether it be lack of ASP, lack of response to ASP, or any other factor that disturbs fatty acid metabolism, such as insulin resistance. We have demonstrated increased postprandial NEFA (57) and abnormal response to ASP (in cells) in such hyperapoB human subjects (5, 58).
In mice, however, this cycle of obesity
NEFA
insulin
resistance/hyperlipidaemia does not appear to be present regardless of
whether the obesity is genetically or diet induced. In our study,
postprandial NEFA increases on either low or high fat diet in
ASP(
/
) mice were not associated with increased glucose/insulin or
fasting hyperlipidaemia. On the other hand, the high fat diet, which
was clearly associated with increased plasma glucose, insulin, and to a
lesser extent cholesterol was not associated with any increase in
fasting or postprandial NEFA as compared with the low fat diet. This is
true for both ASP(+/+) as well as ASP(
/
). There are many other
studies that also demonstrate no change in plasma NEFA consequent to
high fat diet-induced obesity in wild type (+/+) and genetically obese
mutant mice (30, 31, 33, 59-61), and this issue has been discussed in
a recent review (62). Although plasma cholesterol may increase in mice
on a high fat diet (28-31), there is little change in plasma
apoliporpotein B (31). In fact, in a study with 10 different strains of
mice (63) it was shown that even in the presence of high fat and high
cholesterol supplementation, the effect on apoB was not significant (average 15% ± 7% increase), whereas the overall effect on plasma cholesterol, VLDL CHOL, LDL CHOL, and HDL CHOL was highly significant (37 to 103% increase, p < 0.001, calculated by the
author) (63). Thus the finding by Wetsel et al. (47) that
ASP(
/
) does not cause hyperapoB in mice is not unexpected. We could
not find any reports of NEFA-linked dietary/drug/mutations that
resulted in increased apoB hepatic production in mice. Clearly, the
normal metabolic responses to increased NEFA in mice are very different from those in humans, and this may lie in their capacity to increase thermogenesis and oxidation, issues we are now pursuing in the ASP(
/
) mice.
In summary, these results demonstrate that ASP plays an important role
in adipose tissue metabolism, and lack of ASP appears to alter both
nutrient partitioning and the balance of energy intake with body weight
gain and adiposity. An ASP antagonist could provide a pharmacologic
target to alter adipose tissue metabolism.
| |
FOOTNOTES |
|---|
* This study was supported by grants from National Science and Engineering Council of Canada (to K. C.) and Servier Pharmaceuticals (to A. D. S.).The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
A recipient of the Colonel Renouf Fellowship (Royal Victoria
Hospital Research Institute).
¶ Supported by National Institutes of Health Grants DK-35747 and DK-50129 and grants from the U. S. Department of Agriculture and the American Diabetes Association.
A research scholar of the Fonds de Recherche en Sante du
Quebec. To whom correspondence should be addressed: Cardiology, H 7.30, Royal Victoria Hospital, 687 Pine Ave. West, Montreal, Quebec, Canada,
H3A 1A1. Tel.: 514-842-1231 (ext. 5426); Fax: 514-982-0686; E-mail:
mdkc@musica.mcgill.ca.
2 A. D. Sniderman and K. Cianflone, unpublished observations.
3 I. Murray, A. D. Sniderman, and K. Cianflone, manuscript in preparation.
| |
ABBREVIATIONS |
|---|
The abbreviations used are: ASP, acylation stimulating protein; ANOVA, analysis of variance; TG, triglyceride; LF, low fat; HF, high fat; NEFA, plasma non-esterified fatty acids; AUC, area under the curve; CHOL, cholesterol; LDL, low density lipoproteins; VLDL, very LDL; GTT, glucose tolerance test; HDL, high density lipoproteins; LPL, lipoprotein lipase.
| |
REFERENCES |
|---|
|
|
|---|
| 1. | Cianflone, K., Roncari, D. A. K., Maslowska, M., Baldo, A., Forden, J., and Sniderman, A. D. (1994) Biochemistry 33, 9489-9495[CrossRef][Medline] [Order article via Infotrieve] |
| 2. | Murray, I., Parker, R. A., Kirchgessner, T. G., Tran, J., Zhang, Z. J., Westerlund, J., and Cianflone, K. (1997) J. Lipid Res. 38, 2492-2501[Abstract] |
| 3. | Cianflone, K., Maslowska, M., and Sniderman, A. D. (1999) Semin. Cell. Dev. Biol. 10, 31-41[CrossRef][Medline] [Order article via Infotrieve] |
| 4. | Germinario, R., Sniderman, A. D., Manuel, S., Pratt, S., Baldo, A., and Cianflone, K. (1993) Metabolism 40, 574-580 |
| 5. | Zhang, X. J., Cianflone, K., Genest, J., and Sniderman, A. D. (1997) Eur. J. Clin. Invest. 28, 730-739 |
| 6. | Baldo, A., Sniderman, A. D., St-Luce, S., Avramoglu, R. K., Maslowska, M., Hoang, B., Monge, J. C., Bell, A., Mulay, S., and Cianflone, K. (1993) J. Clin. Invest. 92, 1543-1547 |
| 7. |
Van Harmelen, V.,
Reynisdottir, S.,
Cianflone, K.,
Degerman, E.,
Hoffstedt, J.,
Nilsell, K.,
Sniderman, A.,
and Arner, P.
(1999)
J. Biol. Chem.
274,
18243-18251 |
| 8. | Maslowska, M., Sniderman, A. D., Germinario, R., and Cianflone, K. (1997) Int. J. Obes. 21, 261-266[CrossRef][Medline] [Order article via Infotrieve] |
| 9. | Tao, Y. Z., Cianflone, K., Sniderman, A. D., Colby-Germinario, S. P., and Germinario, R. J. (1997) Biochim. Biophys. Acta 1344, 221-229[Medline] [Order article via Infotrieve] |
| 10. |
Lesavre, P. H.,
Hugli, T. E.,
Esser, A. F.,
and Muller-Eberhard, H. J.
(1979)
J. Immunol.
123,
529-534 |
| 11. | Muller-Eberhard, H. J., and Schreiber, R. D. (1980) Adv. Immunol. 29, 1-53[Medline] [Order article via Infotrieve] |
| 12. | Cianflone, K., and Maslowska, M. (1995) Eur. J. Clin. Invest. 25, 817-825[Medline] [Order article via Infotrieve] |
| 13. | Choy, L. N., and Spiegelman, B. M. (1996) Obes. Res. 4, 521-532[Abstract] |
| 14. | Maslowska, M., Scantlebury, T., Germinario, R., and Cianflone, K. (1997) J. Lipid Res. 38, 21-31 |
| 15. |
Scantlebury, T.,
Maslowska, M.,
and Cianflone, K.
(1998)
J. Biol. Chem.
273,
20903-20909 |
| 16. | Charlesworth, J. A., Peake, P. W., Campbell, L. V., Pussell, B. A., O'Grady, S., and Tzilopoulos, T. (1998) Int. J. Obes. Rel. Metab. Dis. 22, 1096-1102[CrossRef] |
| 17. |
Saleh, J.,
Summers, L. K. M.,
Cianflone, K.,
Fielding, B. A.,
Sniderman, A. D.,
and Frayn, K. N.
(1998)
J. Lipid Res.
39,
884-891 |
| 18. | Circolo, A., Garnier, G., Fukuda, K., Wang, X., Tunde, H., Szalai, A. J., Briles, D. E., Volanakis, J. E., Wetsel, R. A., and Colten, H. R. (1999) Immunopharmacology 42, 135-149[CrossRef][Medline] [Order article via Infotrieve] |
| 19. |
Murray, I.,
Sniderman, A. D.,
and Cianflone, K.
(1999)
J. Lipid Res.
40,
1671-1676 |
| 20. |
Murray, I.,
Sniderman, A. D.,
and Cianflone, K.
(1999)
Am. J. Physiol.
277,
E474-E480 |
| 21. |
Lubinski, J. M.,
Wang, L.,
Soulika, A. M.,
Burger, R.,
Wetsel, R. A.,
Colten, H.,
Cohen, G. H.,
Eisenberg, R. J.,
Lambris, J. D.,
and Friedman, H. M.
(1998)
J. Virol.
72,
8257-8263 |
| 22. |
Van Heek, M.,
Compton, D. S.,
France, C. F.,
Tedesco, R. P.,
Fawzi, A. B.,
Graziano, M. P.,
Sybertz, E. J.,
Strader, C. D.,
and Davis, H. R., Jr.
(1997)
J. Clin. Invest.
99,
385-390 |
| 23. |
Ahren, B.,
Mansson, S.,
Gingerich, R. L.,
and Havel, P. J.
(1997)
Am. J. Physiol.
273,
R113-R120 |
| 24. |
Maeda, N. D.,
Li, H.,
Lee, D.,
Oliver, P.,
Quarfordt, S. H.,
and Osada, J.
(1994)
J. Biol. Chem.
269,
23610-23616 |
| 25. |
Shimada, M.,
Shimano, H.,
Gotoda, T.,
Yamamoto, K.,
Kawamura, M.,
Inaba, T.,
and Yazaki, Y.
(1993)
J. Biol. Chem.
268,
17924-17929 |
| 26. | Weinstock, P. H., Bisgaier, C. L., Aalto-Setala, Radner, H., Ramakrishnan, R., Levakfrank, S., Essenburg, A. D., Zechner, R., and Breslow, J. (1995) J. Clin. Invest. 96, 2555-2568 |
| 27. |
Yasushi, I.,
Azrolan, N.,
O'Connell, A.,
Walsh, A.,
and Breslow, J. L.
(1990)
Science
249,
790-793 |
| 28. |
Kopecky, J.,
Hodney, Z.,
Rossmeisl, M.,
Syrovy, I.,
and Kozak, L.
(1996)
Am. J. Physiol.
270,
E768-E775 |
| 29. | Hamann, A., Flier, J. S., and Lowell, B. B. (1996) Endocrinology 137, 21-29[Abstract] |
| 30. |
Hotamisligil, G. S.,
Johnson, R. S.,
Distel, R. J.,
Ellis, R.,
Papaioannou, V. E.,
and Spiegelman, B. M.
(1996)
Science
274,
1377-1379 |
| 31. |
Ranheim, T.,
Dumke, C.,
Schueler, K. L.,
Cartree, G. D.,
and Attie, A. D.
(1997)
Arterioscler. Thromb. Vasc. Biol.
17,
3286-3293 |
| 32. | Gnudi, L., Tozzo, E., Shepherd, P. R., Bliss, J. L., and Kahn, B. B. (1995) Endocrinology 136, 995-1002[Abstract] |
| 33. |
Jensen, D. R.,
Schlaepfer, I. R.,
Morin, C. L.,
Pennington, D. S.,
Marcell, T.,
Ammon, S. M.,
Gutierrez-Hartmann, A.,
and Eckel, R. H.
(1997)
Am. J. Physiol.
273,
R683-R689 |
| 34. |
Morin, C. L.,
Eckel, R. H.,
Marcel, T.,
and Pagliassotti, M. J.
(1997)
Endocrinology
138,
4665-4671 |
| 35. | Frederich, R. C., Hamann, A., Anderson, S., Lollmann, B., Lowell, B. B., and Flier, J. S. (1995) Nat. Med. 1, 1311-1314[CrossRef][Medline] [Order article via Infotrieve] |
| 36. | Surwit, R. S., Feinglos, M. N., Rodin, J., Sutherland, A., Petro, A. E., Opara, E. C., Kuhn, C. M., and Rebuffe-Scrive, M. (1995) Metabolism 44, 645-651[CrossRef][Medline] [Order article via Infotrieve] |
| 37. |
Merkel, M.,
Kako, Y.,
Radner, H.,
Cho, I. S.,
Ramasamy, R.,
Brunzell, J. D.,
Goldberg, I. J.,
and Breslow, J. L.
(1998)
Proc. Natl. Acad. Sci. U. S. A.
95,
13841-13846 |
| 38. | Shimada, M., Ishibashi, S., Yamamoto, K., Kawamura, M., Watanabe, Y., Gotoda, T., Harada, K., Inaba, T., Ohsuga, J., Yazaki, Y., and Yamada, N. (1995) Biochem. Biophys. Res. Commun. 211, 761-766[CrossRef][Medline] [Order article via Infotrieve] |
| 39. | Bjorntorp, P. (1997) Hum. Reprod. 12, 21-25 |
| 40. |
Appel, B.,
and Fried, S. K.
(1992)
Am. J. Physiol.
262,
E695-E699 |
| 41. |
Saxena, U.,
Witte, L. D.,
and Goldberg, I. J.
(1989)
J. Biol. Chem.
264,
4349-4355 |
| 42. | Bengtsson, G., and Olivecrona, T. (1979) FEBS Lett. 106, 345-348[CrossRef][Medline] [Order article via Infotrieve] |
| 43. |
Peterson, J.,
Bihain, B. E.,
Bengtsson-Olivecrona, G.,
Deckelbaum, R. J.,
Carpentier, Y. A.,
and Olivecrona, T.
(1990)
Proc. Natl. Acad. Sci. U. S. A.
87,
909-913 |
| 44. | Lemonnier, D. (1972) J. Clin. Invest. 51, 2907-2915 |
| 45. | Jesmok, G. J., Woods, E. F., Ditzler, W. S., and Walsh, G. (1981) J. Parenter. Enteral Nutr. 5, 200-203[Abstract] |
| 46. | Moller, D. E., Chang, P. Y., Yaspelkis, B. B., Flier, J. S., Wallberg- Hendriksson, H., and Ivy, J. L. (1996) Endocrinology 137, 2397-2405[Abstract] |
| 47. |
Wetsel, R. A.,
Kildsgaard, J.,
Zsigmond, E.,
Liao, W.,
and Chan, L.
(1999)
J. Biol. Chem.
274,
19429-19433 |
| 48. |
Liu, M. S.,
Jirik, F. R.,
LeBoeuf, R. C.,
Henderson, H.,
Castellani, L. W.,
Lusis, A. J.,
Ma, Y.,
Forsythe, I. J.,
Zhang, H.,
Kirk, E.,
Brunzell, J. D.,
and Hayden, M. R.
(1994)
J. Biol. Chem.
269,
11417-11424 |
| 49. | Reue, K., Purcell-Huynh, D. A., Leete, T. H., Doolittle, M. H., Durstenfeld, A., and Lusis, A. J. (1993) J. Lipid Res. 34, 893-903[Abstract] |
| 50. | Jiao, S., Cole, T. G., Kitchens, R. T., Pfleger, B. A., and Schonfeld, G. (1990) Metabolism 39, 155-160[CrossRef][Medline] [Order article via Infotrieve] |
| 51. |
Merkel, M.,
Weinstock, P. H.,
Chajek-Shaul, T.,
Radner, H.,
Yin, B.,
Breslow, J. L.,
and Goldberg, I. J.
(1998)
J. Clin. Invest.
102,
893-901 |
| 52. |
Shepherd, P. R.,
Gnudi, L.,
Tozzo, E.,
Yang, H.,
Leach, F.,
and Kahn, B. B.
(1993)
J. Biol. Chem.
268,
22243-22246 |
| 53. | Despres, J. P. (1991) Curr. Opin. Lipidol. 2, 5-15 |
| 54. | Randle, P. J., Garland, P. B., Hales, C. N., and Newsholme, E. A. (1963) Lancet 1, 785-789[Medline] [Order article via Infotrieve] |
| 55. | Bjorntorp, P. (1990) Arteriosclerosis 10, 493-496[Medline] [Order article via Infotrieve] |
| 56. | McGarry, J. D. (1998) Am. J. Clin. Nutr. 67, 500-504 |
| 57. | Sniderman, A. D., and Kwiterovich, P. O., Jr. (1987) NIH Publication 87-2646 , National Institutes of Health, Bethesda, MD |
| 58. | Cianflone, K., Maslowska, M., and Sniderman, A. D. (1990) J. Clin. Invest. 85, 722-730 |
| 59. | Purcell-Huynh, D. A., Farese, R. V., Jr., Johnson, D. F., Flynn, L. M., Pierotti, V., Newland, D. L., Linton, M. F., Sanan, D. A., and Young, S. G. (1995) J. Clin. Invest. 95, 2246-2257 |
| 60. | Lombardo, Y. B., Hron, W. T., Sobocinski, K. A., and Menahan, L. A. (1983) Horm. Metabol. Res. 16, 37-42 |
| 61. | Menahan, L. A. (1983) Metabolism 32, 172-178[CrossRef][Medline] [Order article via Infotrieve] |
| 62. |
McKnight, S. L.
(1998)
Genes Dev.
12,
3145-3148 |
| 63. | Srivastava, R. A., Jiao, S., Tang, J. J., Pfleger, B. A., Kitchens, R. T., and Schonfeld, G. (1991) Biochim. Biophys. Acta 1086, 29-43[Medline] [Order article via Infotrieve] |
This article has been cited by other articles:
![]() |
S. Paglialunga, A. Fisette, Y. Yan, Y. Deshaies, J.-F. Brouillette, M. Pekna, and K. Cianflone Acylation-stimulating protein deficiency and altered adipose tissue in alternative complement pathway knockout mice Am J Physiol Endocrinol Metab, March 1, 2008; 294(3): E521 - E529. [Abstract] [Full Text] [PDF] |
||||
![]() |
W. Cui, S. Paglialunga, D. Kalant, H. Lu, C. Roy, M. Laplante, Y. Deshaies, and K. Cianflone Acylation-stimulating protein/C5L2-neutralizing antibodies alter triglyceride metabolism in vitro and in vivo Am J Physiol Endocrinol Metab, December 1, 2007; 293(6): E1482 - E1491. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Musaad and E. N. Haynes Biomarkers of Obesity and Subsequent Cardiovascular Events Epidemiol. Rev., May 10, 2007; (2007) mxm005v1. [Abstract] [Full Text] [PDF] |
||||
![]() |